$YTENQ
YIELD10 BIOSCIENCE, INC.

2020 Q2 Form 10-Q Financial Statement

#000112170220000042 Filed on May 15, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2020 Q1 2019 Q1
Revenue $221.0K $179.0K $124.0K
YoY Change -30.5% 44.35% 106.67%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.179M $1.387M $1.186M
YoY Change 15.02% 16.95% -7.05%
% of Gross Profit
Research & Development $1.180M $1.460M $1.220M
YoY Change -0.84% 19.67% 10.91%
% of Gross Profit
Depreciation & Amortization $40.00K $48.00K $50.00K
YoY Change -20.0% -4.0% 6.38%
% of Gross Profit
Operating Expenses $1.179M $1.387M $1.186M
YoY Change 15.02% 16.95% -7.05%
Operating Profit -$2.137M -$2.668M -$2.285M
YoY Change 12.59% 16.76% -1.38%
Interest Expense $0.00 -$920.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net $348.0K -$924.0K $25.00K
YoY Change 1188.89% -3796.0% 0.0%
Pretax Income -$1.789M -$3.592M -$2.260M
YoY Change -4.38% 58.94% -1.31%
Income Tax $7.000K $8.000K $0.00
% Of Pretax Income
Net Earnings -$1.796M -$3.600M -$2.260M
YoY Change -4.01% 59.29% -1.4%
Net Earnings / Revenue -812.67% -2011.17% -1822.58%
Basic Earnings Per Share
Diluted Earnings Per Share -$918.4K -$2.118M -$8.692M
COMMON SHARES
Basic Shares Outstanding 1.970M shares 1.923M shares 12.47M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q2 2020 Q1 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.500M $9.800M $6.100M
YoY Change 97.67% 60.66% -47.41%
Cash & Equivalents $3.290M $4.295M $6.065M
Short-Term Investments $5.200M $5.500M $0.00
Other Short-Term Assets $400.0K $600.0K $500.0K
YoY Change -20.0% 20.0% 25.0%
Inventory
Prepaid Expenses
Receivables $13.00K $54.00K $45.00K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $8.990M $10.51M $6.738M
YoY Change 79.19% 55.97% -44.29%
LONG-TERM ASSETS
Property, Plant & Equipment $978.0K $1.021M $1.335M
YoY Change -24.65% -23.52% -12.52%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $265.0K $272.0K $71.00K
YoY Change 530.95% 283.1% -31.07%
Total Long-Term Assets $4.376M $4.537M $6.357M
YoY Change -28.72% -28.63% -12.2%
TOTAL ASSETS
Total Short-Term Assets $8.990M $10.51M $6.738M
Total Long-Term Assets $4.376M $4.537M $6.357M
Total Assets $13.37M $15.05M $13.10M
YoY Change 19.81% 14.9% -32.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $150.0K $135.0K $12.00K
YoY Change 172.73% 1025.0% -85.0%
Accrued Expenses $882.0K $1.579M $621.0K
YoY Change 50.51% 154.27% -21.19%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.462M $2.187M $1.502M
YoY Change -2.92% 45.61% 4.89%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $17.00K $18.00K $5.400M
YoY Change -99.67% -99.67% 440.0%
Total Long-Term Liabilities $17.00K $18.00K $5.400M
YoY Change -99.67% -99.67% 440.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.462M $2.187M $1.502M
Total Long-Term Liabilities $17.00K $18.00K $5.400M
Total Liabilities $4.879M $5.717M $6.900M
YoY Change -27.2% -17.14% 186.9%
SHAREHOLDERS EQUITY
Retained Earnings -$370.3M -$368.5M -$354.2M
YoY Change 3.99% 4.04% 2.65%
Common Stock $378.9M $378.0M $360.5M
YoY Change 5.08% 4.85% 1.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.487M $9.329M $6.195M
YoY Change
Total Liabilities & Shareholders Equity $13.37M $15.05M $13.10M
YoY Change 19.81% 14.9% -32.27%

Cashflow Statement

Concept 2020 Q2 2020 Q1 2019 Q1
OPERATING ACTIVITIES
Net Income -$1.796M -$3.600M -$2.260M
YoY Change -4.01% 59.29% -1.4%
Depreciation, Depletion And Amortization $40.00K $48.00K $50.00K
YoY Change -20.0% -4.0% 6.38%
Cash From Operating Activities -$1.990M -$2.288M -$2.296M
YoY Change 11.8% -0.35% -24.22%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $42.00K $0.00
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities $250.0K $260.0K $2.750M
YoY Change -125.0% -90.55% -168.92%
Cash From Investing Activities $240.0K $215.0K $2.746M
YoY Change -123.76% -92.17% -168.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 730.0K $928.0K $2.597M
YoY Change -3750.0% -64.27% 1994.35%
NET CHANGE
Cash From Operating Activities -1.990M -$2.288M -$2.296M
Cash From Investing Activities 240.0K $215.0K $2.746M
Cash From Financing Activities 730.0K $928.0K $2.597M
Net Change In Cash -1.020M -$1.200M $3.042M
YoY Change -63.7% -139.45% -144.06%
FREE CASH FLOW
Cash From Operating Activities -$1.990M -$2.288M -$2.296M
Capital Expenditures $0.00 $42.00K $0.00
Free Cash Flow -$1.990M -$2.330M -$2.296M
YoY Change 12.43% 1.48% -24.3%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 USD
CY2020Q1 dei Amendment Flag
AmendmentFlag
false
CY2020Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2020Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020Q1 dei Document Period End Date
DocumentPeriodEndDate
2020-03-31
CY2020Q1 dei Document Type
DocumentType
10-Q
CY2020Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001121702
CY2020Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1970298 shares
CY2020Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q1 dei Entity Registrant Name
EntityRegistrantName
YIELD10 BIOSCIENCE, INC.
CY2020Q1 dei Entity Shell Company
EntityShellCompany
false
CY2020Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
279000 USD
CY2020Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
135000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
72000 USD
CY2020Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
54000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1326000 USD
CY2020Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1579000 USD
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
327000 USD
CY2020Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
22000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0 USD
CY2020Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0 USD
CY2020Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
237000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-126000 USD
CY2020Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-159000 USD
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
360926000 USD
CY2020Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
377963000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
162000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
160000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
349000 USD
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
229016 shares
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3089006 shares
CY2019Q4 us-gaap Assets
Assets
16718000 USD
CY2020Q1 us-gaap Assets
Assets
15046000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
11684000 USD
CY2020Q1 us-gaap Assets Current
AssetsCurrent
10509000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
5700000 USD
CY2020Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
5453000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
5700000 USD
CY2020Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
5475000 USD
CY2019Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
12000 USD
CY2020Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5417000 USD
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4295000 USD
CY2020Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
9770000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3355000 USD
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6397000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5749000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4549000 USD
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3042000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1200000 USD
CY2020Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2846199 shares
CY2019Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2875000 shares
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
337560 shares
CY2020Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2977964 shares
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
933423 shares
CY2020Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1923184 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
933423 shares
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1923184 shares
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
9000 USD
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
19000 USD
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2265000 USD
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3633000 USD
CY2019Q1 us-gaap Costs And Expenses
CostsAndExpenses
2409000 USD
CY2020Q1 us-gaap Costs And Expenses
CostsAndExpenses
2847000 USD
CY2019Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
CY2020Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
30000 USD
CY2019Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
50000 USD
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
48000 USD
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-8.61
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.12
CY2019Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-5000 USD
CY2020Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-55000 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
669000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-18000 USD
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-92000 USD
CY2020Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
388000 USD
CY2020Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
957000 USD
CY2019Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
CY2019 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-9541000 USD
CY2020Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
957000 USD
CY2019Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 USD
CY2020Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-206000 USD
CY2019Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2260000 USD
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3592000 USD
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8000 USD
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-105000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-144000 USD
CY2019Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-49000 USD
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
259000 USD
CY2019Q1 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
13000 USD
CY2020Q1 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
105000 USD
CY2019Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
0 USD
CY2020Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
18000 USD
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
60000 USD
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
69000 USD
CY2019Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
27000 USD
CY2020Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
37000 USD
CY2019Q1 us-gaap Lease Cost
LeaseCost
281000 USD
CY2020Q1 us-gaap Lease Cost
LeaseCost
249000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
5062000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
1540000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
771000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
749000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
726000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
704000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
572000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1077000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
20803000 USD
CY2020Q1 us-gaap Liabilities
Liabilities
5717000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16718000 USD
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15046000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2207000 USD
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2187000 USD
CY2019Q4 us-gaap Long Term Investments
LongTermInvestments
0 USD
CY2020Q1 us-gaap Long Term Investments
LongTermInvestments
0 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2597000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
928000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2746000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
215000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2296000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2288000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-2260000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-3600000 USD
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
25000 USD
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-924000 USD
CY2020Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2285000 USD
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2668000 USD
CY2019Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
259000 USD
CY2020Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
203000 USD
CY2020Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
3985000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
602000 USD
CY2020Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
473000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3619000 USD
CY2020Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3512000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3141000 USD
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2990000 USD
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0724
CY2020Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0724
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y8M15D
CY2020Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y7M9D
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
279000 USD
CY2020Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
186000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
318000 USD
CY2020Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
272000 USD
CY2019Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-5000 USD
CY2020Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-55000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-5000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-33000 USD
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0 USD
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
22000 USD
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0 USD
CY2020Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
18000 USD
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000 USD
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4000 USD
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
42000 USD
CY2019Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
0 USD
CY2020Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
503000 USD
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
137000 USD
CY2019Q4 us-gaap Short Term Investments
ShortTermInvestments
5700000 USD
CY2020Q1 us-gaap Short Term Investments
ShortTermInvestments
5475000 USD
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
796 shares
CY2020Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
296 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
796 shares
CY2020Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
296 shares
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
475000 USD
CY2020Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
560000 USD
CY2019Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
2597000 USD
CY2020Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0 USD
CY2019Q4 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
13018000 USD
CY2019Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
CY2020Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
10000 USD
CY2019Q1 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
2746000 USD
CY2020Q1 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
750000 USD
CY2020Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1638000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1243000 USD
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1021000 USD
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
332000 USD
CY2020Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
254000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-364894000 USD
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-368494000 USD
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
124000 USD
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
179000 USD
CY2019Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1186000 USD
CY2020Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1387000 USD
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
162000 USD
CY2019Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
146000 USD
CY2020Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
183000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 USD
CY2019Q1 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
17000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
25000 USD
CY2019Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2583000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
5698000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
6195000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-4085000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
9329000 USD
CY2020Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.025
CY2019Q1 us-gaap Sublease Income
SubleaseIncome
124000 USD
CY2020Q1 us-gaap Sublease Income
SubleaseIncome
137000 USD
CY2018Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 USD
CY2019Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 USD
CY2019Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 USD
CY2020Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 USD
CY2019Q1 yten Noncash Lease Expense Income
NoncashLeaseExpenseIncome
147000 USD
CY2020Q1 yten Noncash Lease Expense Income
NoncashLeaseExpenseIncome
151000 USD
CY2018Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2019Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2019Q1 yten Private Placement Issuance Costs Incurred During Noncashor Partial Noncash Transaction
PrivatePlacementIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction
14000 USD
CY2020Q1 yten Cost Of Revenue Research And Development Expenses
CostOfRevenueResearchAndDevelopmentExpenses
1460000 USD
CY2019Q1 yten Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-198000 USD
CY2020Q1 yten Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-236000 USD
CY2019Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.01
CY2020Q1 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
5750 shares
CY2020Q1 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0 shares
CY2019Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
5750 shares
CY2020Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2019Q4 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
20000 USD
CY2020Q1 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
125000 USD
CY2019Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
14977000 USD
CY2020Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
0 USD
CY2019Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
24518000 USD
CY2020Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
15934000 USD
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
262567 shares
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1697125 shares
CY2019Q4 yten Accrued Lease Cost
AccruedLeaseCost
51000 USD
CY2020Q1 yten Accrued Lease Cost
AccruedLeaseCost
58000 USD
CY2020Q1 yten Adjustmentsto Additional Paidin Capital Reclassification Of Warrant Liability To Equity
AdjustmentstoAdditionalPaidinCapitalReclassificationOfWarrantLiabilityToEquity
15934000 USD
CY2019Q1 yten Charge For Company Common Stock Match
ChargeForCompanyCommonStockMatch
24000 USD
CY2020Q1 yten Charge For Company Common Stock Match
ChargeForCompanyCommonStockMatch
42000 USD
CY2019Q1 yten Cost Of Revenue Research And Development Expenses
CostOfRevenueResearchAndDevelopmentExpenses
1223000 USD
CY2020Q1 yten Private Placement Issuance Costs Incurred During Noncashor Partial Noncash Transaction
PrivatePlacementIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction
0 USD
CY2019Q1 yten Proceeds From Warrant Exercises Net
ProceedsFromWarrantExercisesNet
0 USD
CY2020Q1 yten Proceeds From Warrant Exercises Net
ProceedsFromWarrantExercisesNet
928000 USD
CY2019Q4 yten Sale Of Stock Gross Consideration Received On Transaction
SaleOfStockGrossConsiderationReceivedOnTransaction
11500000 USD
CY2020Q1 yten Stock Issued During Period Value Conversion Of Temporary Equity
StockIssuedDuringPeriodValueConversionOfTemporaryEquity
0 USD
CY2020Q1 yten Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
928000 USD
CY2020Q1 yten Temporary Equity Shares Conversion To Common Stock
TemporaryEquitySharesConversionToCommonStock
5750 shares
CY2019Q4 yten Temporary Equity Shares Issued Price Per Share
TemporaryEquitySharesIssuedPricePerShare
1000
CY2019Q4 yten Temporary Equity Stock Issued During Period Shares New Issues
TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
5750 shares
CY2019Q4 yten Warrant Obligation Current
WarrantObligationCurrent
0 USD
CY2020Q1 yten Warrant Obligation Current
WarrantObligationCurrent
710000 USD
CY2020Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and investments. The Company has historically invested its cash in highly rated money market funds, corporate debt, federal agency notes and U.S. treasury notes. Investments, when purchased, are acquired in accordance with the Company&#8217;s investment policy which establishes a concentration limit per issuer.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div></div>
CY2020Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of grant revenue and expenses during the reporting periods. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name View Source Status
0001121702-20-000042-index-headers.html Edgar Link pending
0001121702-20-000042-index.html Edgar Link pending
0001121702-20-000042.txt Edgar Link pending
0001121702-20-000042-xbrl.zip Edgar Link pending
ex-101x20200331xpppnote.htm Edgar Link pending
ex-311x20200331.htm Edgar Link pending
ex-312x20200331.htm Edgar Link pending
ex-321x20200331.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
yten-20200331.xml Edgar Link completed
yten-20200331.xsd Edgar Link pending
yten-20200331x10q.htm Edgar Link pending
yten-20200331_cal.xml Edgar Link unprocessable
yten-20200331_def.xml Edgar Link unprocessable
yten-20200331_lab.xml Edgar Link unprocessable
yten-20200331_pre.xml Edgar Link unprocessable